



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6556-67579-01
Application Number	10/753,289
Filing Date	January 5, 2004
First Named Inventor	Watkins
Art Unit	3626 1631
Examiner Name	R Negin

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
RSN		5,952,235	Sep. 14, 1999	Bearer

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee


OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
RSN		Bernhardt <i>et al.</i> , "Purification of fatty acid ethyl esters by solid-phase extraction and high-performance liquid chromatography," <i>J. Chromatography</i> 675:189-196 (1996)
RSN		Stanton <i>et al.</i> , "Interaction of estrogen and 2,3,7,8-tetrachlorodibenzo- <i>p</i> -dioxin (TCDD) with hepatic fatty acid synthesis and metabolism of male chickens (<i>Gallus domesticus</i>)," <i>Comparative Biochemistry and Physiology Part C</i> 129:137-150 (2001)
RSN		Watkins <i>et al.</i> , "Unique Phospholipid Metabolism in Mouse Heart in Response to Dietary Docosahexaenoic or α -Linolenic Acids," <i>Lipids</i> 36(3):247-254 (2001)

EXAMINER SIGNATURE: /Russell S. Negin/

DATE CONSIDERED: 12/04/2006

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



ALTERNATIVE TO PTO/SB/08a/b (07-05)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/753,289
				Filing Date	January 5, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1631
				Examiner Name	M. Moran R Negin
Sheet	1	of	2	Attorney Docket Number	475512000100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RSN	1.	US-2003/0023386-A1	01-30-2003	Aranibar et al.	
RSN	2.	US-6,423,540-B2	07-23-2002	Baur et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
RSN	3.	WO-03/005628-A2,A3	01-16-2003	Lipomics Technologies, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	4.	Boersma, M.G. et al. (January/February 2001). ¹⁹ F NMR Metabolomics for the Elucidation of Microbial Degradation Pathways of Fluorophenols," <i>J. Ind. Microbial. Biotechnol.</i> 26(1/2):22-34.			
RSN	5.	Gates, S.C. et al. (1978). "Quantitative Metabolic Profiling Based on Gas Chromatography," <i>Clinical Chem.</i> 24(10):1663-1673.			
RSN	6.	Griffin, J.L. et al. (June 1, 2001). "Metabolic Profiling of Genetic Disorders: A Multitissue ¹ H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> 293(1):16-21.			
RSN	7.	International Preliminary Examination Report mailed November 29, 2005 for PCT Application No. PCT/US02/21426 filed July 5, 2002, seven pages.			
	8.	International Search Report mailed August 18, 2003 for PCT Application No. PCT/US02/21426 filed July 5, 2002, six pages.			
RSN	9.	Jardine, A. et al. (December 1999). "Fluvastatin in Combination with Cyclosporin in Renal Transplant Recipients: A Review of Clinical and Safety Experience," <i>J. Clinical Pharmacy and Therapeutics</i> 24(6):397-408.			
RSN	10.	Lithell, H. (1993). "Hypertension and Hyperlipidemia: A Review," <i>Am. J. of Hypertension</i> 6(11):303S-308S.			
RSN	11.	Raamsdonk, L.M. et al. (January 2001). "A Functional Genomics Strategy That Uses Metabolome Data to Reveal the Phenotype of Silent Mutations," <i>Nature Biotechnology</i> 19:45-50.			
RSN	12.	Saudek, C.D. et al. (May 1979). "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> 66(1):843-852.			
RSN	13.	Siguel, E.N. et al. (July 1987). "Relative Activity of Unsaturated Fatty Acid Metabolic Pathways in Humans," <i>Metabolism</i> 36(7):664-669.			
RSN	14.	Siguel, E.N. et al. (September 1986). "Monitoring the Optimal Infusion of Intravenous Lipids. Detection of Essential Fatty Acid Deficiency," <i>Arch. Pathol. Lab. Med.</i> 110(9):792-797.			
RSN	15.	Tanaka, K. et al. (April 30, 1982). "Compilation of Gas Chromatographic Retention Indices of 163 Metabolically Important Organic Acids and Their Use in Detection of Patients with Organic			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

pa- 1048021

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/753,289
				Filing Date	January 5, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1631
Examiner Name	M. Moran R Negin				
Sheet	2	of	2	Attorney Docket Number	475512000100

		Acidurias," <i>J. Chromatogr.</i> 239:301-322.	
RSN	16.	Tate, A.R. et al. (May-June 1996). "Lipid Metabolite Peaks in Pattern Recognition Analysis of Tumour <i>in Vivo</i> MR Spectra," <i>Anticancer Res.</i> 16(3B):1575-1579.	
RSN	17.	Toft, P.B. et al. (January/February 1994). "T1, T2, and Concentrations on Brain Metabolites in Neonates and Adolescents Estimated with H-1 MR Spectroscopy," <i>Journal of Magnetic Resonance Imaging</i> 4(1):1-5.	
RSN	18.	Tweeddale, H. et al. (October 1998). "Effect of Slow Growth of Metabolism of <i>Escherichia coli</i> , as Revealed by Global Metabolite Pool ("Metabolome") Analysis," <i>J. Bacteriol.</i> 180(19):5109-5116.	
RSN	19.	Vigneau-Callahan, K.E. et al. (March 2001). "Characterization of Diet-Dependent Metabolic Serotypes: Analytical and Biological Variability Issues in Rats," <i>J. Nutr.</i> 131(3):924S-932S.	
RSN	20.	Waters, N.J. et al. (July 1, 2002). "NMR and Pattern Recognition Studies on Liver Extracts and Intact Livers from Rats Treated with α -Naphthylisothiocyanate," <i>Biochem. Pharm.</i> 64(1):67-77.	
	21.	Watkins, S.M. (September 2000). "Comprehensive Lipid Analysis: A Powerful Metabolic Tool for Predictive and Diagnostic Medicine," <i>IMAJ</i> 2(9):722-724.	duplicate
RSN	22.	Witten, T.A. et al. (1973). "Gas-Chromatographic-Mass-Spectrometric Determination of Urinary Acid Profiles of Normal Young Adults on a Controlled Diet," <i>Clinical Chem.</i> 19(6):586-589.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Russell S. Negin/	Date Considered	12/04/2006
--------------------	--------------------	-----------------	------------

pa- 1048021

NOV 14 2006

ALTERNATIVE TO PTO/SB/09 a/b (07-05)

Substitute for form 1448/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/753,289	
			Filing Date	January 5, 2004	
			First Named Inventor	Steven M. WATKINS	
			Art Unit	1631	
			Examiner Name	R. Negin	
Sheet	1	of	1	Attorney Docket Number	475512000100

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usqlo.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
RSN	1.	Jenkins, G.M. et al. (January 2000). "Testing the Extent of Sequence Similarity Among Viroids, Satellite RNAs, and Hepatitis Delta Virus." <i>J. Mol. Evol.</i> 50(1):98-102.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Russell S. Negin/	Date Considered	12/04/2006
pa-1110526			

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6556-67579
Application Number	10753289
Filing Date	Herewith 1/5/04
First Named Inventor	Watkins Watkins
Art Unit	Not yet assigned. 1631
Examiner Name	Not yet assigned. R. Negin

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
RSN		3,847,550	11/12/1974	Scott <i>et al.</i>
↓		5,075,101	12/24/1991	Siguel
		5,773,300	06/30/1998	Federighi <i>et al.</i>
		6,185,561	02/06/2001	Balaban <i>et al.</i>
		6,188,783	02/13/2001	Balaban <i>et al.</i>
		6,223,127	04/24/2001	Berno
		6,229,911	05/08/2001	Balaban <i>et al.</i>
		6,308,170	10/23/2001	Balaban
↓		6,576,471	06/10/2003	Otvos

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
RSN		WO 99/05574	04 Feb. 1999	PCT
↓		WO 99/05591	04 Feb 1999	PCT
		WO 99/32660	01 July 1999	PCT
		WO 01/04622	18 Jan. 2001	PCT
		WO 01/20043	22 Mar. 2001	PCT
↓		WO 01/23614	05 Apr. 2001	PCT

EXAMINER
SIGNATURE:DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-67579
		Application Number	10753289
		Filing Date	Herewith 1/5/04
		First Named Inventor	Watkins Watkins
		Art Unit	Not yet assigned. 1631
		Examiner Name	Not yet assigned. R. Neglin
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
RSN		Boersma <i>et al.</i> , "19F NMR metabolomics for the elucidation of microbial degradation pathways of fluorophenols," <i>Ind. Microbial Biotechnol.</i> , 26(1/2):22-34, January 2001 (Abstract only)	
		Fiehn, "Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks," <i>Comp. Funct. Genom.</i> , 2:155-168, 2001	
		Griffin <i>et al.</i> , "Metabolic Profiling of Genetic Disorders: A multitissue (1)H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> , 293(1):16-21, June 1, 2001 (Abstract only)	
		Jardine and Holdaas, "Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience," <i>J. Clinical Pharmacy and Therapeutics</i> , 24(6):397-408, December 1999 (Abstract only)	
		Lithell, "Hypertension and hyperlipidemia: A review," <i>Am. J. of Hypertension</i> , 6(11):303S-308S, 1993 (Abstract only)	
		Raamsdonk <i>et al.</i> , "A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations," <i>Nature Biotechnology</i> , 19:45-50, January 2001	
		Saudek and Eder, "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> , 66(5):843-852, 1979 (Abstract only)	
		Siguel <i>et al.</i> , "Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gasliquid chromatography," <i>Clin. Chem.</i> , 33(10):1869-1873, October 1987 (Abstract only)	
		Siguel, "Diagnosing Essential Fatty Acid Deficiency," <i>Circulation</i> , 97(25):2580-2583 1994	
		Siguel <i>et al.</i> , "Monitoring the optimal infusion of intravenous lipids. Detection of essential fatty acid deficiency," <i>Arch. Pathol. Lab. Med.</i> , 110(9):792-797, September 1986 (Abstract only)	
		Siguel and Maclure, "Relative activity of unsaturated fatty acid metabolic pathways in humans," <i>Metabolism</i> , 36(7):664-9, July 1987 (Abstract only)	
		Tanaka and Hine, "Compilation of gas chromatographic retention indices of 163 metabolically important organic acids and their use in detection of patients with organic acidurias," <i>J. Chromatogr.</i> 239:301-322, April 30, 1982 (Abstract only)	
↓		Tate <i>et al.</i> , "Lipid metabolite peaks in pattern recognition analysis of tumour in vivo MR spectra," <i>Anticancer Res.</i> , 16(3B):1575-1579, May-Jun, 1996 (Abstract only)	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-67579
		Application Number	10753289
		Filing Date	Herewith 1/5/04
		First Named Inventor	Watkins Watkins
		Art Unit	Not yet assigned.1631
		Examiner Name	Not yet assigned.R. Negin
RSN		Trethewey, "Gene discovery via metabolic profiling," <i>Curr. Opin. Biotechnol.</i> , 12(2):135-138, April 2001 (Abstract only)	
RSN		Tweeddale <i>et al.</i> , "Effect of slow growth of metabolism of <i>Escherichia coli</i> , as revealed by global metabolite pool ("metabolome") analysis," <i>J. Bacteriol.</i> , 180(19):5109-5116, October 1998 (Abstract only)	
RSN		Vigneau-Callahan <i>et al.</i> , "Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats," <i>J. Nutr.</i> , 131(3):924S-932S, March 2001 (Abstract only)	
RSN		Waters <i>et al.</i> , "NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate," <i>Biochem. Pharm.</i> , 64(1):67-77, July 1, 2002 (Abstract only)	
RSN		Watkins, "Comprehensive Lipid Analysis: A Powerful Metanomic Tool for Predictive and Diagnostic Medicine," <i>IMAJ</i> , 2:722-724, September 2000	
RSN		Watkins <i>et al.</i> , "Individual metabolism should guide agriculture toward foods for improved health and nutrition," <i>Am. J. Clin. Nutr.</i> , 74:283-286, 2001	
RSN		"Functional Genomics in Aberystwyth," http://gepasi.dbs.aber.ac.uk/dbk/fungen.htm , (1 page) printed 06/16/2001	
RSN		Hofestadt and Thelen, "Quantitative Modeling of Biochemical Networks," http://www.bioinfo.de/isb/1998/01/0006/main.html , (12 pages), printed 05/20/2002	
RSN		Siguel, "A New Relationship Between Polyunsaturated Fatty Acids and Total/HDL Cholesterol," <i>Lipids</i> , 31:S51-S56, 1996, http://www.efafod.com/tchdlc.htm , (6 pages) printed 06/09/2001	
RSN		Siguel, "How to evaluate a laboratory that performs fatty acid analysis," http://www.efafod.com/goodlab.htm , (8 pages) printed 06/09/2001	
RSN		Siguel, "High total calories and low EFAs are more likely than fat to be the major culprit in heart disease and cancer," http://www.efafod.com/lowfat.htm , (6 pages), printed 06/09/2001	

EXAMINER SIGNATURE: /Russell S. Negin/	DATE CONSIDERED: 12/04/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	